Holen Sie sich die Stockscreener-App
1.72
1.15%
-0.02
Schlusskurs vom Vortag:
$1.74
Offen:
$1.73
24-Stunden-Volumen:
44,011
Relative Volume:
1.00
Marktkapitalisierung:
$63.30M
Einnahmen:
$24.38M
Nettoeinkommen (Verlust:
$-53.95M
KGV:
-0.6964
EPS:
-2.47
Netto-Cashflow:
$-23.31M
1W Leistung:
-17.31%
1M Leistung:
-18.10%
6M Leistung:
-51.69%
1J Leistung:
-46.58%
1-Tages-Spanne:
$1.70
$1.88
1-Wochen-Bereich:
$1.68
$2.07
52-Wochen-Spanne:
$1.68
$5.24
Elutia Inc Stock (ELUT) Company Profile
Firmenname
Elutia Inc
Sektor
Branche
Telefon
240-247-1143
Adresse
12510 PROSPERITY DRIVE, SILVER SPRING
Vergleichen Sie ELUT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
1.72 | 85.00M | 24.38M | -53.95M | -23.31M | -2.47 |
|
ABT
Abbott Laboratories
|
134.80 | 231.82B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
106.04 | 152.18B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
394.21 | 145.57B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
86.44 | 107.07B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
78.00 | 43.22B | 5.54B | 4.18B | 623.10M | 7.00 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-11-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-02 | Eingeleitet | Cowen | Outperform |
| 2020-11-02 | Eingeleitet | Piper Sandler | Overweight |
| 2020-11-02 | Eingeleitet | Truist | Buy |
Elutia Inc Aktie (ELUT) Neueste Nachrichten
FY2025 EPS Estimates for Elutia Lifted by Cantor Fitzgerald - Defense World
Lake Street Capital Has Lowered Expectations for Elutia (NASDAQ:ELUT) Stock Price - Defense World
Elutia (ELUT) Stock: Lake Street Adjusts Price Target | ELUT Sto - GuruFocus
Elutia (ELUT) Stock: Lake Street Adjusts Price Target | ELUT Stock News - GuruFocus
Elutia (ELUT) Price Target Reduced by Lake Street | ELUT Stock N - GuruFocus
Elutia (ELUT) Price Target Reduced by Lake Street | ELUT Stock News - GuruFocus
Elutia Q1 2025 slides: EluPro sales surge 84% amid overall revenue decline - Investing.com Nigeria
Elutia Inc (ELUT) Q1 2025 Earnings Call Highlights: Strategic Growth and Challenges in Transition - Yahoo Finance
Elutia Inc. Reports Strong Growth in EluPro Sales - TipRanks
Earnings call transcript: Elutia Q1 2025 beats EPS forecast, stock rises - Investing.com
SEC Form 424B5 filed by Elutia Inc. - Quantisnow
Elutia Inc Reports Q1 2025 Earnings: EPS of -$0.21 Meets Estimates, Revenue of $3.1 Million Misses Estimates - GuruFocus
Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales - The Manila Times
Elutia Inc (ELUT) Q1 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
Renaissance Technologies LLC Sells 11,700 Shares of Elutia Inc. (NASDAQ:ELUT) - Defense World
Elutia Inc. Ends Distribution Agreement with LeMaitre - TipRanks
Elutia Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio | ELUT Stock News - GuruFocus
Elutia (ELUT) Resumes Direct Control Over Cardiovascular Portfol - GuruFocus
Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio - The Manila Times
Elutia Ends LeMaitre Partnership: Strategic Shift Promises 80% Margins in $2.9M Cardiovascular Line - Stock Titan
Elutia Inc. Announces First Quarter 2025 Financial Results Release and Conference Call Details - Nasdaq
Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025 - The Manila Times
Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29 | ELUT Stock News - GuruFocus
Elutia's Top Scientist Reveals Drug Development Strategy: Key Regulatory Catalysts in Focus - Stock Titan
Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29 - TradingView
Elutia (ELUT) Begins EluPro Clinical Study to Enhance Patient Ou - GuruFocus
Elutia (ELUT) Begins EluPro Clinical Study to Enhance Patient Outcomes | ELUT Stock News - GuruFocus
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice | ELUT Stock News - GuruFocus
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice - The Manila Times
Elutia Inc. Initiates Clinical Study for EluPro™ to Enhance Cardiac Device Outcomes - Nasdaq
Elutia Begins Landmark Registry Study for Revolutionary CIED Protection Technology EluPro - Stock Titan
Elutia (ELUT) Reports Resilience Amid Global Tariff Changes | EL - GuruFocus
Elutia Confirms No Material Impact from Global Tariffs | ELUT St - GuruFocus
Elutia unaffected by global tariffs, maintains US focus By Investing.com - Investing.com South Africa
Elutia unaffected by global tariffs, maintains US focus - Investing.com Canada
Elutia Unaffected by Global Tariffs Due to US-Based Operations - marketscreener.com
Elutia Confirms No Material Impact from Global Tariffs - The Manila Times
US-Made Medical Devices: How Elutia Dodges Global Tariff Pressures - Stock Titan
Elutia Inc May Offer & Sell Up To $50.0 Million Of Shares Of Class A Common StockSEC Filing - marketscreener.com
Elutia Brokers GPO Agreement with Advantus Health Partners - Medical Product Outsourcing
Eluta Slumps on Recognition - Baystreet.ca
EluPro™ Named as 2025 Edison Award Winner - The Manila Times
Revolutionary Medical Device EluPro Clinches Edison Award: Game-Changer for 600,000 Annual Heart Implants - Stock Titan
Elutia to Participate in Upcoming Investor Conferences - TradingView
Exclusive Investor Access: Elutia CEO to Showcase Drug-Eluting Innovation at Premier Conferences - Stock Titan
AIGH Capital Management LLC Has $11.50 Million Position in Elutia Inc. (NASDAQ:ELUT) - MarketBeat
Elutia to Debut EluPro™ at HRS 2025Experience the Difference Biology Makes - The Manila Times
Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biology Makes - TradingView
Revolutionary Biological CIED Protection: Elutia Unveils Dual-Antibiotic EluPro Technology - Stock Titan
Elutia Inc. reports mixed preliminary 2024 financial results - MSN
Finanzdaten der Elutia Inc-Aktie (ELUT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.85%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):